CSCO Experts’ Voice | Professor Jianming Guo: Outlook on the Development of China’s Prostate Cancer MDT Model and the Future of AI Applications
Editor’s Note: This September, the 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO 2025), one of China’s most prestigious oncology conferences, was successfully held in Jinan. During…
CSCO Experts’ Voice | Professor Xinan Sheng on China-Tailored RCC Guidelines and Innovative Therapies
Editor’s Note: This September, the 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO 2025) was successfully held in Jinan under the theme “Standardized Care, Innovation-Driven Progress.” Following…
Professor Juan Li: Evaluation and Management Strategies for Kidney Injury During Targeted Plus Immunotherapy in Advanced Renal Cell Carcinoma
Editor’s Note: With targeted therapy plus immunotherapy (“targeted-immunotherapy” or T+I) now established as the standard of care for advanced renal cell carcinoma (RCC), treatment-related nephrotoxicity has become an increasingly prominent…
Giuseppe Curigliano on the Clinical Impact and Future of T-DXd Combo Therapy | CSCO 2025
Editor's Note: The Chinese Society of Clinical Oncology (CSCO) Annual Meeting was grandly held in Jinan. This conference brought together authoritative experts in the field of oncology from home and…
Owen O’Connor Provides an In-depth Analysis of the New Paradigm in T-cell Lymphoma Treatment | CSCO 2025
The 2025 Chinese Society of Clinical Oncology (CSCO) Annual Meeting was grandly held in the golden autumn season, gathering top experts from the global field of oncology. In the lymphoma session, the renowned American scholar, Professor Owen O'Connor, delivered a splendid presentation on the topic "REASONS FOR OPTIMISM IN TREATING THE T-CELL MALIGNANCIES: A BIOLOGICAL BASIS COMES INTO FOCUS." He systematically reviewed the historical challenges in the treatment of T-cell lymphoma and emphatically elaborated on why epigenetic targeting will be the key to turning the tide, pointing to a hopeful new path for the future treatment of this disease.